Education
About Us
Working with TipRanks
Follow Us
Roche Holding (RHHBY)
OTHER OTC:RHHBY
Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.75Last Year’s EPS
1.74Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call struck a broadly positive tone: Roche reported solid FY2025 financial results (7% sales growth, +13% core operating profit) and delivered exceptional pipeline momentum with multiple Phase III and regulatory successes (including record progression of NMEs to Phase III and major readouts for fenebrutinib and giredestrant). Management reiterated disciplined capital allocation, upgraded guidance execution and substantial near-term commercial opportunities (AXELIOS sequencing, diagnostics menu expansion, several on-market growth drivers). Key headwinds include significant Diagnostics disruption from China pricing reforms (CHF ~579m impact), weaker operating cash flow driven by working capital build, an increased tax burden affecting EPS momentum, currency and tariff pressures, and regulatory/safety uncertainty in the BTK space. On balance, the quantity and quality of positive clinical readouts, approvals and commercial traction materially outweigh the operational and macro headwinds reported.Company Guidance
Group Revenue and Profit Growth
Group sales grew 7% (FY2025). Pharma sales up 9% and Diagnostics up 2% (would be +7% ex-China). Core operating profit increased 13% with a core operating margin expansion of +1.9 percentage points; core EPS rose ~11%.
Strong Pharma Commercial Performance
Multiple on-market drivers: Phesgo global conversion >50% (now ~54%), Ocrevus passed CHF 7 billion annual sales and is targeted to reach CHF 9 billion by 2029 (including ~CHF 2 billion from subcut), Hematology +15% (CHF 8.6bn), Polivy US patient share ~36%, Xolair grew ~32% (reaching ~CHF 3bn), Evrysdi >21,000 patients on treatment, Vabysmo continued global growth (12% for year) with expected acceleration in 2026.
Exceptional Q4 and Pipeline Readouts
Busy positive Q4 pipeline: two positive Phase III fenebrutinib readouts (PPMS FENtrepid and RMS FENhance 2), positive giredestrant lidERA (adjuvant HR 0.70 for IDFS; OS trending HR 0.79), additional positive Phase III results for Gazyva (INS, SLE), positive Phase III for Enspryng in MOG-AD, PiaSky in aHUS, and positive Phase II CT-388 in obesity.
Record R&D Progress — Late-Stage Acceleration
A record 10 NMEs moved into Phase III (company statement); 19 potential launches planned by decade-end (not all assured). Management notes >60% of NMEs post-bar and 66% of late-stage projects have best-in-disease potential.
Regulatory and Launch Milestones
Regulatory wins and filings: EU approval for Gazyva in lupus nephritis; U.S. and EU approvals for subcutaneous Lunsumio; U.S. filing for giredestrant in post-CDKi metastatic ER+/HER2- breast cancer. Diagnostics approvals include Elecsys dengue test, cobas BV/CV and Mass Spec menu expansion.
Diagnostics Innovation and Commercial Opportunities
Launch of AXELIOS Sequencing Solution (next-generation sequencing) with management citing >CHF 1 billion sales potential, plus a first fully automated clinical mass spec (cobas Mass Spec 601) and new assays (dengue antigen, cobas BV/CV).
Cash Deployment and US Investment Agreement
Agreement with U.S. government provides tariff and demo exemptions in exchange for commitments (including Medicaid rebates) and a pledged US investment of USD 50 billion over five years (R&D and PP&E), supporting manufacturing and R&D expansion in U.S. sites.
Operational Discipline and Guidance Delivery
Company delivered on upgraded guidance: FY sales growth of 7% (mid-single-digit target) and core EPS upgraded and achieved in the double-digit band; 2026 guidance set to mid-single-digit sales growth and high single-digit core EPS growth with expectation to further increase dividend in CHF.
RHHBY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RHHBY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | $54.39 | $57.02 | +4.84% |
Jul 24, 2025 | $41.14 | $41.44 | +0.73% |
Jan 30, 2025 | $38.07 | $39.03 | +2.52% |
Jul 25, 2024 | $37.76 | $38.76 | +2.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Roche Holding (RHHBY) report earnings?
Roche Holding (RHHBY) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is Roche Holding (RHHBY) earnings time?
Roche Holding (RHHBY) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RHHBY EPS forecast?
RHHBY EPS forecast for the fiscal quarter 2026 (Q2) is 1.75.